"Receptors, Estrogen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.
| Descriptor ID |
D011960
|
| MeSH Number(s) |
D12.776.826.750.350 D12.776.930.778.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Estrogen".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Estrogen".
This graph shows the total number of publications written about "Receptors, Estrogen" by people in this website by year, and whether "Receptors, Estrogen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 2 | 2 | 4 |
| 2012 | 1 | 4 | 5 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 1 | 4 | 5 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 3 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptors, Estrogen" by people in Profiles.
-
HC-1119, a deuterated Enzalutamide, inhibits Migration, Invasion and Metastasis of the AR-positive triple-negative breast Cancer cells. Mol Biol Rep. 2022 Oct; 49(10):9231-9240.
-
Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VinoMetro-AGO-B-046. J Cancer Res Clin Oncol. 2021 Nov; 147(11):3391-3400.
-
Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptor-Positive Breast Cancer Patients. Clin Cancer Res. 2020 12 15; 26(24):6523-6534.
-
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast. 2020 Dec; 54:88-95.
-
Progesterone receptor membrane component 1 regulates lipid homeostasis and drives oncogenic signaling resulting in breast cancer progression. Breast Cancer Res. 2020 07 13; 22(1):75.
-
Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. Breast Cancer Res Treat. 2019 Apr; 174(2):453-461.
-
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. Breast. 2018 Feb; 37:42-51.
-
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet. 2017 Dec; 49(12):1767-1778.
-
Prominent Oncogenic Roles of EVI1 in Breast Carcinoma. Cancer Res. 2017 04 15; 77(8):2148-2160.
-
Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer. Menopause. 2017 02; 24(2):203-209.
MeSH information
